Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the business’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $21.59, for a total value of $70,167.50. Following the transaction, the chief financial officer now directly owns 13,000 shares in the company, valued at $280,670. This trade represents a 20.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total value of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total value of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total value of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total value of $130,672.50.

Enliven Therapeutics Stock Up 2.0 %

Shares of NASDAQ ELVN opened at $21.27 on Friday. The stock has a market cap of $1.04 billion, a PE ratio of -11.19 and a beta of 1.04. Enliven Therapeutics, Inc. has a 52-week low of $10.90 and a 52-week high of $30.03. The business has a 50-day moving average price of $23.18 and a 200 day moving average price of $24.31.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ELVN shares. BTIG Research started coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Robert W. Baird upped their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, November 15th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Buy” and an average target price of $38.25.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ELVN. China Universal Asset Management Co. Ltd. increased its stake in Enliven Therapeutics by 14.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock valued at $233,000 after purchasing an additional 1,275 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Enliven Therapeutics by 12.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company’s stock valued at $668,000 after purchasing an additional 2,944 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Enliven Therapeutics by 25.6% in the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after acquiring an additional 3,518 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Enliven Therapeutics by 66.1% in the fourth quarter. SG Americas Securities LLC now owns 16,629 shares of the company’s stock valued at $374,000 after acquiring an additional 6,616 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in Enliven Therapeutics by 44.7% in the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after acquiring an additional 8,540 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.